The goal of this clinical trial is to compare a two-week course of diazoxide (at two
different doses) and placebo in people with insulin resistance-associated non-alcoholic fatty
liver disease (IR-NAFLD). The main questions it aims to answer are how mitigation of
compensatory hyperinsulinemia with diazoxide affects parameters of glucose and lipid
metabolism (how people with IR-NAFLD respond to lowering high insulin levels so that the
investigators can see what happens to how the liver handles fat and sugar).
Participants will:
- Take 27 doses of diazoxide (at 1 mg per kg of body weight per dose [mpk] or 2 mpk) or of
placebo, over 14 days
- Have blood drawn after an overnight fast on six mornings over the two-week study period
- Consume their total calculated daily caloric needs as divided into three meals per day
- Wear a continuous glucose monitor for the two-week study period
Researchers will compare fasting blood tests at intervals during the study period in
participants randomized (like the flip of a coin) to diazoxide 1 mpk, diazoxide 2 mpk, or
placebo, to see how the drug treatment affects plasma glucose, serum insulin, and serum lipid
parameters (triglycerides, free fatty acids, and apolipoprotein B).